We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$248M
Cap. Flow %
2.73%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.41%
2 Miscellaneous 4.48%
3 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
101
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$18.1M 0.2%
1,420,637
+86,836
+7% +$1.14M
ELVN icon
102
Enliven Therapeutics
ELVN
$3.91B
$17.9M 0.2%
1,096,642
+416,666
+61% +$8.66M
HUMA icon
103
Humacyte
HUMA
$153M
$17.4M 0.19%
+1,500,000
New +$17.2M
NRIX icon
104
Nurix Therapeutics
NRIX
$2.58B
$17.3M 0.19%
578,583
+278,583
+93% +$8.6M
FLXN
105
DELISTED
Flexion Therapeutics, Inc.
FLXN
$16.9M 0.19%
2,769,383
– –
RXST icon
106
RxSight
RXST
$234M
$15.8M 0.17%
+1,250,000
New +$17.2M
LUNG icon
107
Pulmonx
LUNG
$82M
$15.7M 0.17%
435,000
+310,000
+248% +$12.2M
BLU
108
DELISTED
BELLUS Health Inc.
BLU
$15M 0.16%
2,454,800
-1,500,000
-38% -$5.69M
MIST icon
109
Milestone Pharmaceuticals
MIST
$115M
$14.8M 0.16%
2,583,821
– –
DMRA
110
Damora Therapeutics
DMRA
$1.53B
$14.7M 0.16%
163,637
– –
DICE
111
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.4M 0.16%
+440,000
New +$15M
CALC icon
112
CalciMedica
CALC
$13.5M
$13.8M 0.15%
59,476
– –
DNTH icon
113
Dianthus Therapeutics
DNTH
$5.86B
$13.8M 0.15%
118,310
-8,800
-7% -$1.03M
CVRX icon
114
CVRx
CVRX
$79.9M
$13.2M 0.15%
799,861
+399,861
+100% +$7.67M
VOR icon
115
Vor Biopharma
VOR
$1.32B
$13.1M 0.14%
41,667
– –
ACHL
116
DELISTED
Achilles Therapeutics
ACHL
$12.3M 0.14%
1,584,845
– –
AMGN icon
117
Amgen
AMGN
$203B
$12.1M 0.13%
57,100
– –
ACRS icon
118
Aclaris Therapeutics
ACRS
$814M
$11.7M 0.13%
651,783
+289,783
+80% +$4.65M
JBIO
119
Jade Biosciences
JBIO
$1.11B
$11.2M 0.12%
15,306
– –
GYRE icon
120
Gyre Therapeutics
GYRE
$709M
$11.1M 0.12%
361,547
+79,067
+28% +$2.6M
NMTR
121
DELISTED
9 Meters Biopharma
NMTR
$11.1M 0.12%
428,299
– –
ALXO icon
122
ALX Oncology
ALXO
$261M
$11.1M 0.12%
150,000
– –
EVH icon
123
Evolent Health
EVH
$423M
$10.7M 0.12%
+345,000
New +$8.28M
IPSC icon
124
Century Therapeutics
IPSC
$359M
$10.2M 0.11%
407,047
– –
WHWK
125
Whitehawk Therapeutics
WHWK
$233M
$10.2M 0.11%
346,262
-1
-0% -$30
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.